Oral Collagen Affects the Upper Dermis
Evidence-led white paper derived from the 2024 peer-reviewed Wiley paper on the AC clinical trial.
Executive Summary
This white paper focuses on the ultrasound component of the clinical trial and asks a focused mechanistic question: where in the dermis might change be occurring? The most useful signal is the low echogenic pixel ratio comparing upper and lower dermis. By week 6, this LEPu/LEPi ratio had decreased by 16.3% from baseline in the daily-use group compared with 9.5% for placebo (p < 0.01). By week 12, the ratio remained lower in the active group than placebo, with borderline between-group significance (p = 0.05).
The authors interpret this pattern as suggesting that collagen-related improvement may be more pronounced in the upper dermal compartment. That interpretation is plausible and scientifically interesting, but it should be framed with discipline. Not every ultrasound marker separated cleanly from placebo, and the week-12 HEP between-group result did not reach conventional significance. The right conclusion is therefore not certainty, but a credible emerging signal of compartment-specific change.
Key Outcomes
| Metric | Result | What it means | |
|---|---|---|---|
| LEPu/LEPi ratio at Week 6 | LEPu/LEPi ratio at Week 6 | 16.3% reduction from baseline at week 6 versus 9.5% for placebo (p<0.01). | This suggests a stronger shift in upper-versus-lower dermal signal in the active group early in the study. |
| Week-12 LEP comparison | Week-12 LEP comparison | 9.3% reduction from baseline in the active group versus 7.8% for placebo (p=0.05). | The directional difference remained present but was less robust statistically by week 12. |
| HEP signal at Week 12 | HEP signal at Week 12 | HEP increased 231% from baseline in the active group versus 176% for placebo (p=0.06). | The pattern was favourable, but the study does not support a strong claim of definitive superiority on this marker. |
Study Snapshot
| | | |
|---|---|---|
| Study design | Study design | Randomised, double-blind, placebo-controlled 12-week clinical trial run under Good Clinical Practice. |
| Participants | Participants | 140 adults enrolled, 130 completed; age 40-60 years; Fitzpatrick I-VI; 90% female / 10% male. |
| Intervention | Intervention | Absolute Collagen supplement providing 8000 mg hydrolysed marine collagen plus 60 mg vitamin C, taken daily or every 48 hours. |
| Core assessments | Core assessments | Confocal microscopy and high-resolution ultrasound of collagen fibers, corneometer hydration, cutometer elasticity, profilometry of wrinkles, expert visual grading, trichoscopy, and self-perception questionnaires. |
Scientific Angle
The most differentiated ultrasound insight in the source paper is not a blanket claim that all collagen markers improved, but a directional pattern suggesting that change may be more evident in the upper dermal compartment.
Discussion
The upper dermis matters because it is closely linked to early visible ageing changes, skin quality, and the interface between dermal matrix organisation and surface appearance. A signal concentrated in this compartment would fit the broader phenotype of better hydration, elasticity, and wrinkle appearance. It would also align with the authors’ discussion around papillary versus reticular fibroblast biology and the possibility that papillary dermal remodelling could be especially relevant to visible change.
At the same time, ultrasound data in skin can be noisy. Echogenic markers reflect overlapping biological features, including hydration, inflammation, elastosis, and collagen organisation. That complexity shows up here: some markers improved from baseline in both groups, and HEP did not achieve a clearly significant between-group separation. For that reason, the ultrasound story should be positioned as supportive mechanistic evidence rather than as the lead efficacy claim.
Strategically, this angle is still valuable. This research gives a more nuanced scientific framing than generic collagen-density language. The disciplined version of the message is that the trial generated an emerging ultrasound signal consistent with preferential improvement in the upper dermis, warranting follow-up rather than overclaiming a settled fact.
Limitations and Evidence Discipline
- The ultrasound interpretation is biologically plausible but not definitive; several echogenic markers did not cleanly separate from placebo.
- The week-12 HEP between-group result was not statistically significant at p < 0.05.
- Compartment-specific dermal interpretation remains inferential and would be stronger with follow-up imaging or dedicated mechanistic studies.
Conclusion
“The ultrasound data do not prove a settled compartment-specific mechanism, but they do suggest a credible emerging pattern: the dermal response to daily supplementation may be more evident in the upper dermis than in deeper compartments.”
Source note: derived from the peer-reviewed 2024 clinical paper only; no unsupported external claims have been added.
Reilly, David M., Kynaston, Liane, Naseem, Salma, Proudman, Eva, Laceby, Darcy, A Clinical Trial Shows Improvement in Skin Collagen, Hydration, Elasticity, Wrinkles, Scalp, and Hair Condition following 12-Week Oral Intake of a Supplement Containing Hydrolysed Collagen, Dermatology Research and Practice, 2024, 8752787, 12 pages, 2024. https://doi.org/10.1155/2024/8752787